Sensei Biotherapeutics to Present at BIO CEO & Investor Conference
GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb 5, 2019--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 3:45 p.m. ET in New York, NY.
About Sensei Biotherapeutics Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development, for solid tumors and hematological cancers. These programs target ASPH, a novel embryonic antigen. Sensei’s precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190205005225/en/
CONTACT: Media Contact:
The Yates Network
Stern Investor Relations, Inc.
KEYWORD: UNITED STATES NORTH AMERICA MARYLAND NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL
SOURCE: Sensei Biotherapeutics
Copyright Business Wire 2019.
PUB: 02/05/2019 08:30 AM/DISC: 02/05/2019 08:30 AM